Genetic polymorphisms of melatonin receptors 1A and 1B may result in disordered lipid metabolism in obese patients with polycystic ovary syndrome

Xu,Xiu‑Hua; Kou,Lian‑Cui; Wang,Hai‑Mei; Bo,Chun‑Mei; Song,Xiao‑Cui

doi:10.3892/mmr.2019.9872

Genetic polymorphisms of melatonin receptors 1A and 1B may result in disordered lipid metabolism in obese patients with polycystic ovary syndrome

Authors:
- Xiu‑Hua Xu
- Lian‑Cui Kou
- Hai‑Mei Wang
- Chun‑Mei Bo
- Xiao‑Cui Song
View Affiliations

Affiliations: Obstetrics and Gynecology Clinic, Dongying People's Hospital, Dongying, Shandong 257091, P.R. China, Department of Blood Rheumatism, Dongying People's Hospital, Dongying, Shandong 257091, P.R. China, Marketing and Customer Service, Dongying People's Hospital, Dongying, Shandong 257091, P.R. China, Department of Reproductive Medicine, Dongying People's Hospital, Dongying, Shandong 257091, P.R. China
Published online on: January 17, 2019 https://doi.org/10.3892/mmr.2019.9872
Pages: 2220-2230
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Polycystic ovary syndrome (PCOS) is a condition in which a woman's levels of the sex hormones (estrogen and progesterone) are out of balance, leading to the growth of ovarian cysts. PCOS can affect the menstrual cycle, fertility, cardiac function and even appearance of women. Therefore, we aimed to explore the genetic polymorphism of the melatonin receptors 1A and 1B in obese patients with PCOS to identify a new theoretical basis for its treatment. Patients presenting with PCOS (n=359) were enrolled and classified into an obese OB‑PCOS group [body mass index (BMI) of PCOS patients ≥25 kg/m2] or a nonobese NOB‑PCOS group, and 215 oviduct infertile patients who experienced normal ovulation were used as the control group. All baseline characteristics, endocrine hormone levels, lipid and glucose metabolism, and insulin indices were measured. The genotypes of rs2119882 within the MTNR1A gene and of rs10830963 within the MTNR1B gene were determined by PCR‑RFLP; the genotype frequency and the difference in the distribution of allele frequency were compared. For rs2119882, C allele carriers who were not diagnosed with PCOS had an increased risk of developing PCOS, and C allele carriers with PCOS had an increased risk of developing OB‑PCOS. For rs10830963, G allele carriers who were not diagnosed with PCOS had an increased risk of developing PCOS. The TT genotype in rs2119882 and the CC genotype in rs10830963 were protective factors for OB‑PCOS, and increased levels of LH, testosterone, and estradiol and abnormal menstruation were key risk factors for PCOS. Furthermore, the TT genotype at the rs2119882 site was the key protective factor for OB‑PCOS patients. Our study found that MTNR1A rs2119882 and MTNR1B rs10830963 could increase the risk for PCOS and cause glycolipid metabolism disorder in PCOS patients.

View Figures

View References

1	Swaroop A, Jaipuriar AS, Gupta SK, Bagchi M, Kumar P, Preuss HG and Bagchi D: Efficacy of a novel fenugreek seed extract (Trigonella foenum-graecum, Furocyst) in polycystic ovary syndrome (PCOS). Int J Med Sci. 12:825–831. 2015. View Article : Google Scholar : PubMed/NCBI
2	March WA, Moore VM, Willson KJ, Phillips DI, Norman RJ and Davies MJ: The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 25:544–551. 2010. View Article : Google Scholar : PubMed/NCBI
3	Goodarzi MO, Dumesic DA, Chazenbalk G and Azziz R: Polycystic ovary syndrome: Etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 7:219–231. 2011. View Article : Google Scholar : PubMed/NCBI
4	Stener-Victorin E, Holm G, Janson PO, Gustafson D and Waern M: Acupuncture and physical exercise for affective symptoms and health-related quality of life in polycystic ovary syndrome: Secondary analysis from a randomized controlled trial. BMC Complement Altern Med. 13:1312013. View Article : Google Scholar : PubMed/NCBI
5	Costello MF, Misso ML, Wong J, Hart R, Rombauts L, Melder A, Norman RJ and Teede HJ: The treatment of infertility in polycystic ovary syndrome: A brief update. Aust N Z J Obstet Gynaecol. 52:400–403. 2012. View Article : Google Scholar : PubMed/NCBI
6	Wehr E, Pieber TR and Obermayer-Pietsch B: Effect of vitamin D3 treatment on glucose metabolism and menstrual frequency in polycystic ovary syndrome women: A pilot study. J Endocrinol Invest. 34:757–763. 2011.PubMed/NCBI
7	Gourgari E, Spanakis E and Dobs AS: Pathophysiology, risk factors, and screening methods for prediabetes in women with polycystic ovary syndrome. Int J Womens Health. 8:381–387. 2016. View Article : Google Scholar : PubMed/NCBI
8	Li C, Shi Y, You L, Wang L and Chen ZJ: Melatonin receptor 1A gene polymorphism associated with polycystic ovary syndrome. Gynecol Obstet Invest. 72:130–134. 2011. View Article : Google Scholar : PubMed/NCBI
9	Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM and Pandi-Perumal SR: Melatonin-a pleiotropic, orchestrating regulator molecule. Prog Neurobiol. 93:350–384. 2011. View Article : Google Scholar : PubMed/NCBI
10	McClay DR: Evolutionary crossroads in developmental biology: Sea urchins. Development. 138:2639–2648. 2011. View Article : Google Scholar : PubMed/NCBI
11	Carcangiu V, Luridiana S, Vacca GM, Daga C and Mura MC: A polymorphism at the melatonin receptor 1A (MTNR1A) gene in Sarda ewes affects fertility after AI in the spring. Reprod Fertil Dev. 23:376–380. 2011. View Article : Google Scholar : PubMed/NCBI
12	Tobias DK, Gaskins AJ, Missmer SA, Hu FB, Manson JE, Buck Louis GM, Zhang C and Chavarro JE: History of infertility and risk of type 2 diabetes mellitus: A prospective cohort study. Diabetologia. 58:707–715. 2015. View Article : Google Scholar : PubMed/NCBI
13	Ren T, Zhu Y and Kan J: Zanthoxylum alkylamides activate phosphorylated AMPK and ameliorate glycolipid metabolism in the streptozotocin-induced diabetic rats. Clin Exp Hypertens. 39:330–338. 2017. View Article : Google Scholar : PubMed/NCBI
14	Lyssenko V, Nagorny CL, Erdos MR, Wierup N, Jonsson A, Spégel P, Bugliani M, Saxena R, Fex M, Pulizzi N, et al: Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet. 41:82–88. 2009. View Article : Google Scholar : PubMed/NCBI
15	Slominski RM, Reiter RJ, Schlabritz-Loutsevitch N, Ostrom RS and Slominski AT: Melatonin membrane receptors in peripheral tissues: Distribution and functions. Mol Cell Endocrinol. 351:152–166. 2012. View Article : Google Scholar : PubMed/NCBI
16	Slominski AT, Zmijewski MA, Semak I, Kim TK, Janjetovic Z, Slominski RM and Zmijewski JW: Melatonin, mitochondria, and the skin. Cell Mol Life Sci. 74:3913–3925. 2017. View Article : Google Scholar : PubMed/NCBI
17	Ying X, Qian Y, Jiang Y, Jiang Z, Song Z and Zhao C: Association of the apolipoprotein B/apolipoprotein A-I ratio and low-density lipoprotein cholesterol with insulin resistance in a Chinese population with abdominal obesity. Acta Diabetol. 49:465–472. 2012. View Article : Google Scholar : PubMed/NCBI
18	Chin R and Miyazaki S: Criteria of obesity and obesity disease in Japan. Nihon Rinsho. 67:297–300. 2009.(In Japanese). PubMed/NCBI
19	Ferriman D and Gallwey JD: Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 21:1440–1447. 1961. View Article : Google Scholar : PubMed/NCBI
20	Lucky AW, McGuire J, Rosenfield RL, Lucky PA and Rich BH: Plasma androgens in women with acne vulgaris. J Invest Dermatol. 81:70–74. 1983. View Article : Google Scholar : PubMed/NCBI
21	Stumvoll M, Mitrakou A, Pimenta W, Jenssen T, Yki-Järvinen H, Van Haeften T, Renn W and Gerich J: Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity. Diabetes Care. 23:295–301. 2000. View Article : Google Scholar : PubMed/NCBI
22	Abbasi F, Blasey C, Feldman D, Caulfield MP, Hantash FM and Reaven GM: Low circulating 25-hydroxyvitamin D concentrations are associated with defects in insulin action and insulin secretion in persons with prediabetes. J Nutr. 145:714–719. 2015. View Article : Google Scholar : PubMed/NCBI
23	Macut D, Bjekić-Macut J, Rahelić D and Doknić M: Insulin and the polycystic ovary syndrome. Diabetes Res Clin Pract. 130:163–170. 2017. View Article : Google Scholar : PubMed/NCBI
24	Genazzani AR and Genazzani AD: Polycystic ovary syndrome: From contraception to hormone replacement therapy. Front Gynecol Endocrinol. Springer International Publishing. 2015. View Article : Google Scholar : PubMed/NCBI
25	Wu D, Kimura F, Takashima A, Shimizu Y, Takebayashi A, Kita N, Zhang G and Murakami T: Intake of vinegar beverage is associated with restoration of ovulatory function in women with polycystic ovary syndrome. Tohoku J Exp Med. 230:17–23. 2013. View Article : Google Scholar : PubMed/NCBI
26	Costello M, Shrestha B, Eden J, Sjoblom P and Johnson N: Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database Syst Rev. CD0055522007.PubMed/NCBI
27	Esmaeilzadeh S, Andarieh MG, Ghadimi R and Delavar MA: Body mass index and gonadotropin hormones (LH & FSH) associate with clinical symptoms among women with polycystic ovary syndrome. Glob J Health Sci. 7:101–106. 2014. View Article : Google Scholar : PubMed/NCBI
28	Ramezanali F, Khalili G, Arabipoor A, Bagheri Lankarani N and Moini A: Relationships between serum luteinizing hormone level, endometrial thickness and body mass index in polycystic ovary syndrome patients with and without endometrial hyperplasia. Int J Fertil Steril. 10:36–41. 2016.PubMed/NCBI
29	Kawwass JF, Sanders KM, Loucks TL, Rohan LC and Berga SL: Increased cerebrospinal fluid levels of GABA, testosterone and estradiol in women with polycystic ovary syndrome. Hum Reprod. 32:1450–1456. 2017. View Article : Google Scholar : PubMed/NCBI
30	Njelekela MA, Negishi H, Nara Y, Sato T, Tomohiro M, Kuga S, Noguchi T, Kanda T, Yamori M, Mashalla Y, et al: Obesity and lipid profiles in middle aged men and women in Tanzania. East Afr Med J. 79:58–64. 2002. View Article : Google Scholar : PubMed/NCBI
31	Kalani Z, Salimi T and Rafiei M: Comparison of obesity indexes BMI WHR and WC in association with Hypertension: Results from a blood pressure status survey in Iran. J Cardiovasc Dis Res. 6:72–77. 2015. View Article : Google Scholar
32	Zaki M, Kholoussi S, Ismail S, Raouf HA, Helwa I, Hassan N, Youness E, Mohamed NA, Kamal S, Yousef W, et al: Metabolic abnormalities in young Egyptian women with polycystic ovary syndrome and their relation to ADIPOQ, gene variants and body fat phenotype. Egypt J Med Hum Genet. 16:367–374. 2015. View Article : Google Scholar
33	Jaworek J, Nawrot-Porabka K, Leja-Szpak A, Bonior J, Szklarczyk J, Kot M, Konturek SJ and Pawlik WW: Melatonin as modulator of pancreatic enzyme secretion and pancreatoprotector. J Physiol Pharmacol. 58 Suppl 6:S65–S80. 2007.
34	Slominski AT, Hardeland R, Zmijewski MA, Slominski RM, Reiter RJ and Paus R: Melatonin: A cutaneous perspective on its production, metabolism, and functions. J Invest Dermatol. 138:490–499. 2018. View Article : Google Scholar : PubMed/NCBI
35	Slominski AT, Semak I, Fischer TW, Kim TK, Kleszczynski K, Hardeland R and Reiter RJ: Metabolism of melatonin in the skin: Why is it important? Exp Dermatol. 26:563–568. 2017. View Article : Google Scholar : PubMed/NCBI
36	Lin FY, Lin CW, Yang SF, Lee WJ, Lin YW, Lee LM, Chang JL, Weng WC, Lin CH and Chien MH: Interactions between environmental factors and melatonin receptor type 1A polymorphism in relation to oral cancer susceptibility and clinicopathologic development. PLoS One. 10:e01216772015. View Article : Google Scholar : PubMed/NCBI
37	Song X, Sun X, Ma G, Sun Y, Shi Y, Du Y and Chen ZJ: Family association study between melatonin receptor gene polymorphisms and polycystic ovary syndrome in Han Chinese. Eur J Obstet Gynecol Reprod Biol. 195:108–112. 2015. View Article : Google Scholar : PubMed/NCBI
38	Park HJ, Park JK, Kim SK, Cho AR, Kim JW, Yim SV and Chung JH: Association of polymorphism in the promoter of the melatonin receptor 1A gene with schizophrenia and with insomnia symptoms in schizophrenia patients. J Mol Neurosci. 45:304–308. 2011. View Article : Google Scholar : PubMed/NCBI
39	Del Campo JA, Ampuero J, Rojas L, Conde M, Rojas A, Maraver M, Millán R, García-Valdecasas M, García-Lozano JR, González-Escribano MF and Romero-Gómez M: Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism. Aliment Pharmacol Ther. 37:74–80. 2013. View Article : Google Scholar : PubMed/NCBI
40	Chen Z, Liu W, Sun X and Zhu L: Clinical study on the association between pregnancy-induced hypertension and insulin resistance. Exp Ther Med. 13:2065–2070. 2017. View Article : Google Scholar : PubMed/NCBI
41	Diamanti-Kandarakis E: Insulin resistance in PCOS. Endocrine. 30:13–17. 2006. View Article : Google Scholar : PubMed/NCBI
42	Li Q, Yin RX, Yan TT, Miao L, Cao XL, Hu XJ, Aung LH, Wu DF, Wu JZ and Lin WX: Association of the GALNT2 gene polymorphisms and several environmental factors with serum lipid levels in the Mulao and Han populations. Lipids Health Dis. 10:1602011. View Article : Google Scholar : PubMed/NCBI
43	Li C, Shi Y, You L, Wang L and Chen ZJ: Association of rs10830963 and rs10830962 SNPs in the melatonin receptor (MTNR1B) gene among Han Chinese women with polycystic ovary syndrome. Mol Hum Reprod. 17:193–198. 2011. View Article : Google Scholar : PubMed/NCBI